Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ.
Steinhubl SR, et al. Among authors: lincoff am.
Circulation. 2001 May 29;103(21):2572-8. doi: 10.1161/01.cir.103.21.2572.
Circulation. 2001.
PMID: 11382726
Clinical Trial.